Table 1.
Summary of reported cases of neuropsychiatric adverse effects associated with glucocorticoid eye drop use.
| Authors, year | Age in years (sex) | Type of glucocorticoid eye drops (dose) | Past psychiatric history | Neuropsychiatric manifestations | Management | Outcome |
|---|---|---|---|---|---|---|
| Mok and Malladi, 2013 [6] | 81 (female) | Prednisolone (1% four times/day) | Chronic schizophrenia and single episode of hypomania | Mania | (i) Prednisolone discontinued (ii) Uptitration of baseline psychotropic medications |
Full recovery |
| Kumagai and Ichimiya, 2014 [7] | 76 (male) | Fluorometholone (N/A) | N/A | Mania | (i) Fluorometholone discontinued (ii) Sodium valproate (200 mg/day) administered |
Full recovery |
| Farooq and Dallol, 2014 [8] | 90 (female) | Fluorometholone (0.1% three times/day) | None | Acute confusion | (i) Fluorometholone discontinued | Full recovery |
| Cakici and Hergüner, 2015 [9] | 15 (male) | Fluorometholone (0.1% three times/day) | Attention-deficit/hyperactivity disorder | Hypomania | (i) Fluorometholone discontinued (ii) Quetiapine (100 mg/day) administered |
Full recovery |
| This case | 75 (female) | Prednisolone (1% four times/day) | None | Mania | (i) Prednisolone discontinued (ii) Olanzapine (5 mg/day) administered |
Full recovery |
N/A: not available.